微創腦科學 (2172.HK)

8.930 -0.550 (-5.80%) 收市：04:08PM HKT

微創腦科學

Zhangjiang High-tech Park
No. 1661 Zhangdong Road Pudong New Area
Shanghai
China
86 21 3895 4600
https://www.medneurotech.com

版塊: Healthcare
行業: Medical Devices
全職員工: 571

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Zhiyong Xie	CEO, Executive Director & Chairman of MicroPort NeuroTech	2.96M	無	1978
Mr. Yiqun Wang	First VP, Director of Engineering & Tech. Dept, Head of R&D Team and Executive Director	2.13M	無	1966
Ms. Zhuoping Hou	Advanced Director of Finance	無	無	1978
Dr. Wangcai Liao	Chief Technology Officer	無	無	無
Ms. Zaoli Wu	Senior Director of Human Resources & Administration	無	無	1983
Mr. Lei Duan	Chief Marketing Officer and SVP of Sales & Promotion of Neurovascular Disease Treatment Solutions	無	無	1982
Mr. Qingwei Sun	Non-Executive Director & Director of MicroPort NeuroTech	無	無	1983
Ms. Yin Shan Hui A.C.I.S., A.C.S., HKICS, ICSA	Company Secretary	無	無	1969

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; NUMEN Silk; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; Comaneci, an adjustable temporary coil embolization; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial stent a balloon-expandable stent to treat intracranial atherosclerotic disease; Bridge, a rapamycin target eluting vertebral artery stent system; and Diveer, an intracranial balloon catheter to treat cerebral atherosclerosis stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; X-Track, and distal access catheter product; W-track, an intracranial aspiration catheter; and balloon protection guide catheter; and Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. Further, it provides Asahi Neurovascular Guidewires and U-track support catheter. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.

公司管治

截至 無 止，微創腦科學 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。